ArticleACS nano2014
Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes.
Article in ACS nano, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 157 citations in OpenAlex.
- Smart Polymer Nanoparticles: Targeting Macrophages/Fibroblasts and Modulating the Microenvironment for Rheumatoid Arthritis Therapy.International journal of nanomedicine · 2026Review
- Nanotechnology-driven delivery of dexamethasone for arthritis: The role of liposomes.EXCLI journal · 2026Review
- Desmoplastic tumor priming using clinical-stage corticosteroid liposomes.Cell biomaterials · 2025Article
- Nanostructured lipid carriers in Rheumatoid Arthritis: treatment, advancements and applications.Inflammopharmacology · 2025Review
- Structured Polymers Enable the Sustained Delivery of Glucocorticoids within the Intra-Articular Space.Advanced healthcare materials · 2025Article
- Research Trends and Developments in Nanomaterials for Rheumatoid Arthritis: A Comprehensive Bibliometric Analysis.Drug design, development and therapy · 2025Article
- Selective Glycopolymer Inhibitors of Galectin-3: Supportive Anti-Cancer Agents Protecting Monocytes and Preserving Interferon-Gamma Function.International journal of nanomedicine · 2025Article
- Therapeutic Potential of Nanocarriers in the Management of Rheumatoid Arthritis.Current rheumatology reviews · 2025Review
- Nanotherapeutic kidney cell-specific targeting to ameliorate acute kidney injury.Kidney international · 2024Article
- Prodrug-based nanomedicines for rheumatoid arthritis.Discover nano · 2024Review
- Drug Delivery System Approaches for Rheumatoid Arthritis Treatment: A Review.Mini reviews in medicinal chemistry · 2024Review
- Supercritical Antisolvent Precipitation of Corticosteroids/β-Cyclodextrin Inclusion Complexes.Polymers · 2023Article
- Exploring the role of exosomes in rheumatoid arthritis.Inflammopharmacology · 2023Review
- Hollow-polydopamine-nanocarrier-based near-infrared-light/pH-responsive drug delivery system for diffuse alveolar hemorrhage treatment.Frontiers in chemistry · 2023Article
- Preclinical Dose-Escalation Study of ZSJ-0228, a Polymeric Dexamethasone Prodrug, in the Treatment of Murine Lupus Nephritis.Molecular pharmaceutics · 2021Article
- Hyaluronic Acid-Dexamethasone Nanoparticles for Local Adjunct Therapy of Lung Inflammation.International journal of molecular sciences · 2021Article
- Advances of nanomaterials-based strategies for fighting against COVID-19.View (Beijing, China) · 2021Review
- Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.Advanced drug delivery reviews · 2021Review
- Inflammation-responsive delivery systems for the treatment of chronic inflammatory diseases.Drug delivery and translational research · 2021Review
- Recent Progress in Nanotechnology for COVID-19 Prevention, Diagnostics and Treatment.Nanomaterials (Basel, Switzerland) · 2021Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 5 countries.
Funding
Abstract
As an emerging research direction, nanomedicine has been increasingly utilized to treat inflammatory diseases. In this head-to-head comparison study, four established nanomedicine formulations of dexamethasone, including liposomes (L-Dex), core-cross-linked micelles (M-Dex), slow releasing polymeric prodrugs (P-Dex-slow), and fast releasing polymeric prodrugs (P-Dex-fast), were evaluated in an adjuvant-induced arthritis rat model with an equivalent dose treatment design. It was found that after a single i.v. injection, the formulations with the slower drug release kinetics (i.e., M-Dex and P-Dex-slow) maintained longer duration of therapeutic activity than those with relatively faster drug release kinetics, resulting in better joint protection. This finding will be instructional in the future development and optimization of nanomedicines for the clinical management of rheumatoid arthritis. The outcome of this study also illustrates the value of such head-to-head comparison studies in translational nanomedicine research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.